T1	p 81 136	postmenopausal breast cancer survivors with bone loss :
T2	p 381 434	223 postmenopausal breast cancer survivors . Subjects
T3	p 584 624	postmenopausal breast cancer survivors (
T4	p 862 870	subjects
T5	p 875 892	also participated
T6	p 896 911	strength/weight
T7	p 921 927	( ST )
T8	p 1111 1131	Postmenopausal BCS (
T9	p 1429 1434	women
T10	p 2227 2245	postmenopausal BCS
T11	i 20 35	weight training
T12	i 227 252	weight training exercises
T13	i 283 320	risedronate , calcium , and vitamin D
T14	i 467 475	exercise
T15	i 666 677	risedronate
T16	i 680 703	calcium , and vitamin D
T17	i 896 937	strength/weight training ( ST ) exercises
T18	i 1164 1202	exercise plus medication or medication
T19	i 1263 1357	calcium and 400 IU of vitamin D daily and 35 mg of risedronate weekly , and the exercise group
T20	i 1371 1387	had ST exercises
T21	i 1401 1402	.
T22	i 2165 2199	Strength/weight training exercises
T23	o 39 77	bone mineral density and bone turnover
T24	o 349 377	bone mineral density ( BMD )
T25	o 498 501	BMD
T26	o 531 534	BMD
T27	o 718 744	bone mineral density ( BMD
T28	o 840 853	bone turnover
T29	o 963 966	BMD
T30	o 992 1007	bone turnover ;
T31	o 1097 1100	BMD
T32	o 1375 1387	ST exercises
T33	o 1504 1513	in BMD at
T34	o 1518 1527	total hip
T35	o 1544 1549	spine
T36	o 1591 1601	Alkphase B
T37	o 1617 1626	serum NTx
T38	o 1691 1700	in BMD at
T39	o 1705 1712	femoral
T40	o 1738 1741	hip
T41	o 1831 1839	Alkphase
T42	o 1857 1866	Serum NTx
T43	o 1891 1937	changes in BMD and bone turnover with exercise
T44	o 2036 2039	BMD
T45	o 2212 2223	loss of BMD